Liquidia Corporation Common Stock (LQDA)

Price$41.40

Favorite Metrics

Price vs S&P 500 (26W)62.63%

Price vs S&P 500 (4W)3.71%

Market Capitalization$3.54B

All Metrics

Book Value / Share (Quarterly)$0.51

P/TBV (Annual)13.48x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)114.96%

Cash Flow / Share (Quarterly)$-0.48

Price vs S&P 500 (YTD)13.68%

Gross Margin (TTM)91.64%

Net Profit Margin (TTM)-43.53%

EPS (TTM)$-0.81

10-Day Avg Trading Volume1.02M

EPS Excl Extra (TTM)$-0.81

Revenue Growth (5Y)192.46%

EPS (Annual)$-0.80

ROI (Annual)-66.82%

Gross Margin (Annual)91.64%

Net Profit Margin (5Y Avg)-387.10%

Cash / Share (Quarterly)$2.19

Revenue Growth QoQ (YoY)3054.65%

ROA (Last FY)-55.78%

Revenue Growth TTM (YoY)1031.18%

EBITD / Share (TTM)$-0.59

ROE (5Y Avg)-103.21%

Operating Margin (TTM)-32.45%

Cash Flow / Share (Annual)$-1.20

P/B Ratio79.00x

P/B Ratio (Quarterly)67.05x

Net Income / Employee (Annual)$-0

EV / Revenue (TTM)22.33x

Net Interest Coverage (TTM)-2.93x

ROA (TTM)-25.32%

EPS Incl Extra (Annual)$-0.80

Current Ratio (Annual)4.40x

Quick Ratio (Quarterly)1.80x

3-Month Avg Trading Volume1.61M

52-Week Price Return190.09%

Revenue / Employee (TTM)$1

Tangible BV / Share (Quarterly)$0.48

P/S Ratio (Annual)22.33x

Asset Turnover (Annual)0.06x

52-Week High$46.67

Operating Margin (5Y Avg)-368.89%

EPS Excl Extra (Annual)$-0.80

CapEx CAGR (5Y)53.23%

26-Week Price Return66.61%

Quick Ratio (Annual)4.26x

13-Week Price Return9.62%

Total Debt / Equity (Annual)1.49x

Current Ratio (Quarterly)2.01x

Enterprise Value$3,535.812

Revenue / Share Growth (5Y)142.81%

Asset Turnover (TTM)0.58x

Book Value / Share Growth (5Y)-6.05%

Revenue / Employee (Annual)$1

Pretax Margin (Annual)-43.53%

Cash / Share (Annual)$2.07

3-Month Return Std Dev60.64%

Gross Margin (5Y Avg)78.34%

Net Income / Employee (TTM)$-0

ROE (Last FY)-166.61%

Net Interest Coverage (Annual)-2.93x

EPS Basic Excl Extra (Annual)$-0.80

Receivables Turnover (TTM)5.57x

Total Debt / Equity (Quarterly)4.28x

EPS Incl Extra (TTM)$-0.81

Receivables Turnover (Annual)3.86x

ROI (TTM)-32.44%

P/S Ratio (TTM)22.33x

Pretax Margin (5Y Avg)-387.10%

Revenue / Share (Annual)$1.84

Tangible BV / Share (Annual)$0.87

Forward P/E17.17x

Price vs S&P 500 (52W)160.26%

Year-to-Date Return16.32%

5-Day Price Return-0.50%

EPS Normalized (Annual)$-0.80

ROA (5Y Avg)-50.21%

Net Profit Margin (Annual)-43.53%

Month-to-Date Return6.31%

Cash Flow / Share (TTM)$-0.86

EBITD / Share (Annual)$-0.60

Operating Margin (Annual)-32.45%

LT Debt / Equity (Annual)0.92x

ROI (5Y Avg)-61.19%

LT Debt / Equity (Quarterly)2.97x

EPS Basic Excl Extra (TTM)$-0.81

P/TBV (Quarterly)71.79x

P/B Ratio (Annual)12.93x

Inventory Turnover (TTM)1.10x

Pretax Margin (TTM)-43.53%

Book Value / Share (Annual)$0.91

Price vs S&P 500 (13W)8.93%

Beta0.46x

Revenue / Share (TTM)$1.82

ROE (TTM)-209.33%

52-Week Low$11.85

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.13

Industry Peers — Pharmaceuticals(308)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
LQDALiquidia Corporation Common Stock	22.33x	1031.18%	91.64%	—	$41.40
LLYEli Lilly & Co.	13.08x	44.70%	83.04%	27.59%	$903.99
JNJJohnson & Johnson	5.94x	7.87%	67.95%	14.90%	$234.54
ABBVABBVIE INC.	6.04x	8.57%	71.62%	-2.88%	$208.99
MRKMerck & Co., Inc.	4.41x	1.31%	78.55%	21.23%	$115.46
AZNAstraZeneca PLC	5.28x	8.63%	81.31%	21.88%	$200.47
NVSNovartis AG	4.98x	8.91%	75.82%	15.26%	$149.73
NVONovo-Nordisk A/S	3.62x	6.43%	80.98%	20.66%	$40.93
ABTAbbott Laboratories	3.66x	6.59%	56.50%	8.20%	$95.47
PFEPfizer Inc.	2.47x	-1.64%	75.81%	-3.51%	$27.22
BMYBristol-Myers Squibb Co.	2.47x	-0.22%	72.63%	—	$58.96

About

Liquidia Corp is a biopharmaceutical company focused on pulmonary hypertension and related lung diseases. The company leverages proprietary PRINT technology to engineer uniform drug particles, enabling its lead product YUTREPIA (treprostinil) inhalation powder, while also generating revenue from Treprostinil Injection sales.